Evidence map›Paper›PMID 39478856›Full record

ArticleFrontiers in immunology2024

Exopeptidase combination enhances the degradation of isotopically labelled gluten immunogenic peptides in humans.

Sulayman Mourabit, Sarah Römer, Erin R Bonner, Fabian Winter, Julian Tschollar, Mladen V Tzvetkov, Werner Weitschies, Stefan Engeli, Werner Tschollar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sulayman MourabitAMYRA Biotech AG, Basel, Switzerland.
Sarah RömerDepartment of General Pharmacology, Institute of Pharmacology Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Erin R BonnerAMYRA Biotech AG, Basel, Switzerland.
Fabian WinterDepartment of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Greifswald, Germany.
Julian TschollarAMYRA Biotech AG, Basel, Switzerland.
Mladen V TzvetkovDepartment of General Pharmacology, Institute of Pharmacology Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Werner WeitschiesDepartment of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, Center of Drug Absorption and Transport (C_DAT), University of Greifswald, Greifswald, Germany.
Stefan EngeliDepartment of Clinical Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Werner TschollarAMYRA Biotech AG, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Celiac disease is a common autoimmune-like enteropathy caused by an aberrant response to incompletely digested dietary gluten. Gluten immunogenic peptides including the immunodominant 33-mer are thought to be resistant to proteolytic digestion by human gastrointestinal peptidases. We developed a novel enzyme therapy approach to support gluten peptide digestion using a combination of two tandem-acting exopeptidases, AMYNOPEP, that complement the intrinsic enzymatic activity of intestinal brush border enterocytes. Methods: We evaluated the effects of AMYNOPEP supplementation on 33-mer degradation Results: AMYNOPEP achieved rapid, complete amino-to-carboxyl terminal degradation of the 33-mer Conclusions: AMYNOPEP achieved complete degradation of the 33-mer into single amino acids and dipeptides

Indexed as

Celiac DiseaseGlutensAdultCross-Over StudiesExopeptidasesFemaleHumansIsotope LabelingMaleMiddle AgedPeptidesProteolysisTandem Mass SpectrometryYoung AdultExopeptidasesGlutensPeptides33-merceliac diseaseenzyme supplementationenzyme therapyexopeptidaseglutenglutenasegluten immunogenic peptide

Identifiers

PMID39478856
PMCPMC11522800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.